Differential levels of soluble endoglin (CD105) in myeloid malignancies

Journal of Cellular Physiology

Volumn 194, Issue 2, 2003, Pages 171-175

  Calabrò, Luana ^a   Fonsatti, Ester ^a   Bellomo, Giacomo ^b   Alonci, Andrea ^b   Colizzi, Francesca ^a   Sigalotti, Luca ^a   Altomonte, Maresa ^a   Musolino, Caterina ^b   Maio, Michele ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOT HYBRIDIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; MYELOFIBROSIS; NEOVASCULARIZATION (PATHOLOGY); POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CHRONIC DISEASE; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; RECEPTORS, CELL SURFACE; SOLUBILITY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0037293932     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.10200     Document Type: Article

References (27)

1. Adam PJ, Clesham GJ, Weissberg PL. 1998. Expression of endoglin mRNA and protein in human vascular smooth muscle cells. Biochem Biophys Res Commun 247:33-37.
2. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S, Keating M, Freireich E, Albitar M. 2000. Angiogenesis in acute and chronic leukemias and myelodys-plastic syndromes. Blood 96:2240-2245.
3. Bühring HJ, Müller CA, Letarte M, Gougos A, Saalmüller A, van Agthoven AJ, Busch FW. 1991. Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia 5:841-847.
4. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES, Thorpe PE. 1995. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy. Clin Cancer Res 1:1623-1634.
5. Cheifetz S, Bellón T, Calés C, Vera S, Bernabéu C, Massagué J, Letarte M. 1992. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 267:19027-19030.
6. Chen Y, Lu L, Wang L. 1998. Study on gene expression of TGF beta 1 and its receptor in leukemia cells and the serum TGF beta 1 level in the patients with acute leukemia. Zhonghua Xue Ye Xue Za Zhi 19:576-580.
7. De Nardo C, Fonsatti E, Sigalotti L, Calabrò L, Colizzi F, Cortini E, Coral S, Altomonte M, Maio M. 2002. Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells. J Cell Physiol 190:200-206.
8. Folkman J. 1990. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6.
9. Fonsatti E, Jekunen AP, Kairemo KJA, Coral S, Snellman M, Nicotra MR, Natali PG, Altomonte M, Maio M. 2000. Endoglin is a suitable target for efficient imaging of solid tumors: In vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 6:2037-2043.
10. Fonsatti E, Del Vecchio L, Altomonte M, Sigalotti L, Nicotra MR, Coral S, Natali PG, Maio M. 2001. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 188:1-7.
11. Gougos A, Letarte M. 1988. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 141:1925-1933.
12. Haruta Y, Seon BK. 1986. Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci USA 83:7898-7902.
13. Jacobsen SEW, Ruscetti FW, Roberts AB, Keller JR. 1993. TGF-β is a bidirectional modulator of cytokine receptor expression on murine bone marrow cells. Differential effects of TGF-beta 1 and TGF-beta 3. J Immunol 151:4534-4544.
14. Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM. 1994. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 25:1794-1798.
15. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, Bundred N. 1999. Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59:856-861.
16. Lastres P, Letamendía A, Zhang H, Rius C, Almendro N, Raab U, López LA, Langa C, Fabra A, Letarte M, Bernabéu C. 1996. Endoglin modulates cellular response to TGF-β1. J Cell Biol 133:1109-1121.
17. Li C, Hampson IN, Hampson L, Kumar P, Bernabéu C, Kumar S. 2000a. CD 105 antagonizes the inhibitory signaling of transforming growth factor β1 on human vascular endothelial cells. FASEB J 14:55-64.
18. Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N, Kumar S. 2000b. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 89:122-126.
19. Lo Pardo C, Altomonte M, Boccuni P, Di Noto R, Vacca C, Maio M, Del Vecchio L. 1997. CD105 Workshop: Expression of CD105 on acute leukemia blast cells: Application for minimal residual disease detection. In: Kishimoto T, Kikutani H, von dem Borne AEGKr, Goyert SM, Mason DY, Miyasaka M, Moretta L, Okumura K, Shaw S, Springer TA, Sugamura K, Zola H, editors. Leucocyte Typing VI. White Cell Differentiation Antigens. New York & London: Garland Publishing, Inc. p 711-712.
20. Lundberg GL, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. 2000. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 157:15-19.
21. Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A, Sedlacek HH, Müller R, Adamkiewicz J. 1999. Elevated expression of endoglin, a component of the TGF-β-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 81:568-572.
22. Nilsen-Hamilton M. 1990. Transforming growth factor-β and its actions on cellular growth and differentiation. Curr Top Dev Biol 24:95-136.
23. Rajkumar SV, Mesa RA, Tefferi A. 2002. A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies. J Hematother Stem Cell Res 11:33-47.
24. Robledo MM, Hidalgo A, Lastres P, Arroyo AG, Bernabéu C, Sanchez-Madrid F, Teixido J. 1996. Characterization of TGF-β 1 binding proteins in human bone marrow stromal cells. Br J Haematol 93:507-514.
25. Rokhlin OW, Cohen MB, Kubagawa H, Letarte M, Cooper MD. 1995. Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J Immunol 154:4456-4465.
26. Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, Seon BK. 2001. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 7:524-532.
27. Wickenhauser C, Willienhof A, Jungheim K, Lorenzen J, Ruskowski H, Hansmann ML, Thiele J, Fischer R. 1995. Detection and quantification of transforming growth factor beta (TGF-beta) and platelet-derived growth factor (PDGF) release by normal human megakaryocytes. Leukaemia 9:310-315.